May 9th 2025
A coalition of over 100 US companies is supporting the federal initiative to end the HIV epidemic by 2030, but legal and funding threats now jeopardize this progress and the significant health and economic benefits it promises.
Undermining HIV Prevention Now Will Cost Billions Later
April 7th 2025The 15th anniversary of the Affordable Care Act is overshadowed by threats to HIV prevention efforts, including a looming Supreme Court case that could eliminate no-cost access to preexposure prophylaxis and other preventive services. Simultaneously, deep federal cuts and restructuring have destabilized critical public health infrastructure, jeopardizing decades of progress in the fight against HIV.
Read More
The Case for HIV Prevention and Screening: Pay Today or Pay Tomorrow
March 16th 2025Carl Schmid, executive director, HIV + Hepatitis Policy Institute, explains how a Supreme Court case could have far reaching implications for greater health screenings and preventative services beyond HIV and hepatitis.
Read More
Summarizing SGLT-2 Inhibitor Usage in People With Diabetes and HIV
January 16th 2025In persons living with HIV and diabetes, the management of diabetes is lagging behind the evidence. Despite SGLT-2 inhibitors demonstrating robust clinical data in the general population, they are grossly underused in persons with HIV and diabetes.
Read More
INSTIs and Cardiovascular Outcomes: More Complexity
October 28th 2024The significance of antiretroviral therapy (ART) has been a game changer for people living with HIV (PLWH). Still, there are some cardiovascular risks associated with different ART classes—particularly protease inhibitors (PIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and integrase strand transfer inhibitors (INSTIs). Authors review a piece in the literature around this area of study.
Read More